The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV). Promoters, sponsors and/or operators must be willing to substantially co-fund the project.

The project must have a proven public health impact and potential market prospects.

The borrower must be established and operating in one or several of the Member States and H2020 Associated Countries. The project and/or the Investigational Programme (IP) development, such as clinical trials, can be undertaken outside Member States and H2020 Associated Countries.

Projects must relate to investment in the field of infectious diseases (ID) with an established proof of concept. For example, the project must develop innovative vaccines, medicines, medical or diagnostic devices, or infrastructure in the field of ID that require clinical testing or are ready for later stage clinical trials.

We can also provide finance for:

• novel research infrastructure that provides facilities, resources and related services for use by the scientific community to conduct top-level research in the ID field; or
• investments supporting pre-clinical research in such cases whereby a high unmet medical need is being addressed and potential results providing benefits for the respective patient populations should be feasible within a 5-year time horizon; or
• European manufacturing facilities to enable commercial production of essential vaccines, diagnostics and treatments and pharmaceutical ingredients.

We will select the operations to be financed by taking into account aspects such as the operation’s risk profile and bankability prospects, the overall IDFF funding available, portfolio composition and other transactions in the pipeline.

• Germany: EIB provides finance of €15 million for Spindiag’s novel PCR diagnostics system
• Team Europe pledges support for eradicate Malaria, an initiative aiming to facilitate the development and production of a highly efficacious malaria vaccine
• Germany: EIB provides Immunic with up to €24.5 million to support ongoing development of a potential COVID-19 therapy
• Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment
• Poland: EIB lends up to EUR 10 million to Scope Fluidics to develop diagnostics equipment for infectious diseases
• Netherlands: Europe supports AM-Pharma through EUR 24m InnovFin facility
• EIB Group will rapidly mobilise up to EUR 40 billion to fight crisis caused by Covid-19 and calls on Member States to set up a further guarantee for SME and mid-cap support from EIB Group and national promotional banks
• Netherlands: ISA Pharmaceuticals B.V. receives EUR 20m loan from EIB
• Belgium: Univercells boosted by EUR 20m European financing to accelerate the delivery of its vaccine portfolio
• Austria: EU supports F2G Biotech with EUR 24 million for antifungal research and innovation
• Belgium: European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects
• Denmark: EIB supports biopharmaceutical company AntibioTx in fighting multi-drug resistant bacteria
• France: EIB grants Da Volterra EUR 20m loan to speed up development of innovative solutions for the prevention and treatment of antibiotic-resistant infections
• Israel: EIB supports Late-Stage Development and Production of BiondVax’s Universal Flu Vaccine Candidate
• Spain: EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain
• Finland: InnovFin: European support for innovation
• France: EIB lends EUR 20m toTransgene
• Sweden: EIB supports Cavidi’s development of HIV viral load monitoring device

• InnovFin Infectious Diseases